On the downside, GSK's COVID-19 therapy Xevudy (sotrovimab) saw a slump in demand, with sales falling to £500 million from £1.3 billion in the first quarter of 2022, and GSK is expecting the ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

Breakthrough Adjuvant AB-801 Secures“Bioprocessing Excellence in Taiwan” HonorTAIPEI, Taiwan, March 13, 2025 (GLOBE NEWSWIRE) ...

GSK’s fourth-quarter Vaccine sales declined 12% due to lower sales of its RSV vaccine Arexvy and shingles vaccine, Shingrix. Arexvy generated £158 million during the quarter, down 69% year ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

GlaxoSmithKline Pharmaceuticals Limited is ... In 2022-23, the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults who are 50 ...

PHILADELPHIA, February 17, 2025--PENMENVY, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY ViiV Healthcare, the global specialist HIV company majority ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.